Cochrane's strength lies in its collaborative, global community. Cochrane Geographic Groups represent Cochrane in their host countries, advocate for the use of Cochrane evidence in health policy and practice, and support Cochrane's members and supporters who live there. Here, we spotlight the Navarre Associate Centre, a key player within Cochrane Iberoamérica, dedicated to enhancing evidence-based healthcare in Spain.

Established in 2015 through a formal agreement between the Health Department of the Government of Navarre and Cochrane Iberoamerica, the Navarre Associate Centre has been a cornerstone in advancing evidence-based practices in the region. The Centre also serves as the host for the Spanish satellite of Cochrane Hypertension, launched following an invitation from the group's base in Canada.

Juan Erviti, Director of the Navarre Associate Centre, highlights the Centre's commitment to rigorous research and knowledge translation: "Our work is deeply rooted in the belief that healthcare decisions should be guided by the best available evidence. By providing training on systematic reviews, GRADE, and critical appraisal, we empower healthcare professionals across Spain to make informed decisions that ultimately improve patient outcomes."

The Centre's contributions to the field are significant, offering systematic review training to health professionals, medical associations, university students, and Cochrane members. In addition, the Centre supports postgraduate research, including Master’s and doctoral theses. The Navarre Associate Centre has produced both Cochrane and non-Cochrane systematic reviews, with a particular focus on hypertension. Their recent publications include critical reviews on blood pressure targets in individuals with chronic renal disease and for people with hypertension and cardiovascular disease, the impact of pharmacotherapy on hypertension-induced left ventricular hypertrophy, and on alcohol intake reduction for controlling hypertension.

The Navarre Associate Centre is also a member of the newly formed thematic group, Cochrane Heart, Stroke, and Circulation, and the Spanish network for the Improvement of the Appropriateness of Clinical Practice (MAPAC). This engagement offers unique opportunities for knowledge translation both locally and nationally, contributing to a broader impact across Spain.

Luis Carlos Saiz, Managing Editor of the Spanish satellite of the Cochrane Hypertension Group, underscores the importance of collaboration in amplifying the Centre’s impact: "Our involvement in networks like MAPAC and the Spanish Medicines Agency’s BIFAP database allows us to work closely with clinicians and researchers, ensuring that our evidence synthesis work is directly applicable to clinical practice. These collaborations are crucial in driving improvements in healthcare delivery."

The Navarre Associate Centre plays a crucial role in shaping clinical practice within the Navarre Health Service. Clinicians propose relevant topics for the "Committee for the Improvement of the Appropriateness of Clinical Practice" (MAPAC) to address. The Centre's members, also part of the MAPAC committee, develop evidence synthesis reports based on both Cochrane and non-Cochrane systematic reviews. These reports form the basis of recommendations and guidelines, which are then transformed into legally binding resolutions by the Managing Director of the Navarre Health Service, ensuring effective implementation and positive impact on healthcare practices.

Looking forward, the Centre aims to align its activities more closely with the needs of clinicians and the goals of Cochrane. As part of the newly approved Cochrane Iberoamerica Evidence Synthesis Unit, the Centre is poised to contribute even more substantially to evidence synthesis in the region.

For those interested in getting involved, the Navarre Associate Centre welcomes collaboration and inquiries. "We are always looking to expand our network and invite healthcare professionals and researchers to join us in our mission to enhance evidence-based healthcare," adds Saiz.

• Visit the Cochrane Iberoamérica website
• Cochrane the Navarre Associate Centre via Juan Erviti (jervitil@navarra.es) or Luis Carlos Saiz (lsaizfer@navarra.es).
• Find a Cochrane Geographic Group in your country

Friday, August 23, 2024

Tuesday, August 13, 2024

Tuesday, August 13, 2024

Wednesday, August 7, 2024

心臓発作（急性心筋梗塞）に対して、骨髄から採取した幹細胞を心臓へ移植する治療は、安全かつ効果的な治療法か？ 要点 - 幹細胞による治療は、急性心筋梗塞の臨床成績の改善にはつながらない。 - 幹細胞による治療は、急性心筋梗塞の治療期間中に有害事象を引き起こすことはほとんどない。 急性心筋梗塞が引き起こす問題は何か？ 急性心筋梗塞は、心臓の筋肉（心筋）に血液を供給する動脈の閉塞によって引き起こされる。新しい治療法が進歩しているとはいえ、急性心筋梗塞を起こした人の多くは心臓の機能が低下し、余命も短くなる。 急性心筋梗塞はどのように治療されているのか？ 現在の急性心筋梗塞に対する標準的な治療法は、経皮的冠動脈形成術（PCI）である。小さな風船を用いて閉塞した動脈を再び開き、ステントと呼ばれる小さな管を挿入して動脈の開通状態を維持する方法である。 どのような治療法が研究されているのか？ 骨髄由来細胞は、損傷した心筋を修復する能力があることから、心臓発作の追加治療として研究されており、心臓の損傷に関係する血液中の化学物質や、心機能を測定する画像検査などの結果に有益な効果が見られることがわかっている。しかし、死亡や再入院、または別の重大な心臓疾患（脳卒中や他の心臓発作など）を起こす可能性といった重要な臨床成績に影響を与えるかどうかについてはわかっていない。 何を調べようとしたのか？ すべての研...

Tuesday, August 6, 2024

アトピー性皮膚炎に対する外用薬（皮膚に直接塗る薬）の比較 要点： 強力な副腎皮質ステロイド外用薬(以下ステロイド）、JAK（ヤヌスキナーゼ）阻害薬、タクロリムス0.1％（いずれも免疫系を抑制する薬剤）は、アトピー性皮膚炎の徴候や症状を軽減するのに一貫して有効である。 灼熱感（ほてり感）や刺激感（ヒリヒリ感）などの望ましくない効果（副作用）は、タクロリムス、ピメクロリムス、クリサボロールでより起こりやすく、ステロイドでは起こりにくい；皮膚が薄くなるなど、他の副作用は、強力なステロイドを長期使用（長期塗布）した場合にのみ起こりやすい。 アトピー性皮膚炎に対する抗炎症外用薬の長期的な有効性と安全性については不確実であるため、製品の入手可能性、費用面、個人の優先事項など、他の要因も考慮するべきである。 何を調べたかったのか？ アトピー性皮膚炎は、（現在のところ）治らないとされている炎症性の皮膚疾患である。アトピー性皮膚炎の症状を軽減するとされているさまざまな皮膚に直接塗る（外用）抗炎症治療薬（抗炎症外用薬）を比較した。アトピー性皮膚炎がある人に対して最も有効性が高くかつ最も安全な抗炎症外用薬を見つけたかった。 実施したこと 年齢や湿疹の重症度を問わず、アトピー性皮膚炎の人が参加したランダム化試験を対象とした。外用治療（塗り薬）は少なくとも1週間使用する必要があり、他の抗炎症治療または無治...

SARS-CoV-2感染者の死亡率や重症・重篤な新型コロナウイルス感染症への悪化の予測において、ルーチンの臨床検査はどの程度正確か？ ルーチンの臨床検査とは何か？ ルーチンの臨床検査とは、患者の健康状態に関する情報を提供する、一般的に行われる一連の血液検査である。これらの検査は、病気の特定や健康状態のモニターに使用することができる。 知りたかったこと 外来や救急外来を受診した患者の中から、重症の新型コロナウイルス感染症(COVID-19)を発症したり死亡したりするリスクの高い患者を特定することが重要である。それらは、臨床医が患者に入院が必要かどうかを判断する際に役立つ。SARS-CoV-2の感染が確定診断された患者において、ルーチン検査が死亡率や悪化の予測に十分正確かどうかを知りたかった。 実施したこと SARS-CoV-2が確認された患者において、ルーチンの臨床検査が死亡率や悪化をどの程度予測できるかを評価した研究を検索した。世界中のあらゆる場所で行われた、どのようなデザインの研究も対象とした。年齢、性別は問わない。 わかったこと 53種類の異なるルーチンの臨床検査を対象とした64件の研究が見つかった。これらの研究では、ルーチンの臨床検査が死亡率、悪化、あるいはその両方をどの程度予測できるかを評価していた。合計71,170人の患者が対象となり、そのうち8,169人（11.5％）...

HIV感染者が禁煙をするためのさまざまな方法は、どの程度効果的で、有害事象を引き起こすのか？ 要点 - バレニクリン（ニコチンへの欲求を抑える薬）は、プラセボ（偽薬）と比較すると、タバコを吸うHIV感染者の禁煙を6か月以上助ける可能性が高く、重篤な有害事象のリスクを増加させない可能性がある。 - 禁煙するのに使われている他の方法が、HIV感染者の6か月以上の禁煙に役立つかどうかは、十分な情報が得られなかったのでわからない。 - 今後の研究では、より大規模で、重篤な有害事象に関する情報を提供する必要がある。 なぜHIV感染者のタバコ使用が問題なのか？ 世界中のHIV感染者の多くが、タバコ、つまりタバコの葉およびその製品を、喫煙する、噛む、吸い込む、嗅ぐことで使用している。タバコの使用はさまざまな健康問題を引き起こし、多くの死者を出しているが、人はタバコに含まれるニコチンによって中毒になり、禁煙することが難しくなる。HIV感染者の喫煙率は一般集団人口の約4倍である。残念なことに、有効なHIV治療が受けられるようになっても、HIV感染者は喫煙が原因で約12年間の人生を失う可能性があり、これはHIV感染そのものが原因で失われる可能性のある年数の2倍以上である。 HIV感染者はどうすればタバコを止められるのか？ タバコの使用を止めるのに使われる方法には、ニコチン置換療法（NRT）、バレニク...

反復経頭蓋磁気刺激（rTMS）は成人の心的外傷後ストレス障害（PTSD）に対する有効かつ安全な治療法か？ 要点 - 成人において、rTMSはおそらくプラセボrTMS（偽刺激）と比較して、治療終了時までにPTSD症状の重症度を軽減させない。しかし、これらの結果は、治療の実施方法に大きなばらつきがあったことと、参加者の数が少なかったことにより、限定的なものであった。 - PTSDに対するrTMSの研究では、重篤な有害事象が起こることはまれであった。 - 成人のPTSDに対するrTMSについて、さらなる研究が必要である。今後の研究で、有害事象についてより詳細に報告され、PTSDの重症度を評価するために治療後に参加者をより長く追跡調査することができれば有益であろう。 心的外傷後ストレス障害とは何か？ 心的外傷後ストレス障害（PTSD）は、心的外傷を伴う出来事に遭遇した後に発症する、苦痛や障害を伴う症状を特徴とする精神疾患である。PTSDを治療せずに放置すると、PTSDがある多くの人は何年も苦しむことになる。 PTSDはどのように治療されるのか？ PTSDには薬物療法や精神療法などいくつかの治療法がある。しかし、既存の治療法では脱落率が高く、これは治療への忍容性に問題があり、症状が続く可能性があることを示唆している。PTSDにはより効果的な治療法が必要である。反復経頭蓋磁気刺激（rTMS）...

Specifications: Fixed-term contract (12 months) – part time
Salary: £35,000 per annum full time equivalent (to be pro rated)
Location: Remote working (UK, Germany or Denmark)
Closing date:  9 August 2024
    
Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters around the world. Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into five directorates: Evidence Production and Methods, Publishing and Technology, Development, Central Executive office and Finance and Corporate Services.

The Consumer Support Officer will work closely with Cochrane’s Consumer Engagement Manager to support the involvement of consumers (patients, carers and the public) in the Wellcome-funded Global Alliance for Living Evidence on aNxiety, depressiOn and pSychosis (GALENOS) project, including in systematic reviews about mental health topics. Support of consumers in this work will involve connecting consumers with lived experience of mental health challenges to researchers, developing learning resources to support consumer involvement in systematic reviews, and generally promoting patient and public involvement in the systematic review space.
      
Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everything we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.

You can expect:

• An opportunity to truly impact health globally.
• A flexible work environment
• A comprehensive onboarding experiences.
• An environment where people feel welcome, heard, and included, regardless of their differences.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations, and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply click here,  
• The deadline to receive your application is 9 August, 2024.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Read our Recruitment Privacy Statement

Wednesday, July 31, 2024 Category: Jobs

ビタミンDの補充は、妊娠中の女性およびその児に有益か、有害か、あるいは影響がないか？ 要点 妊娠中のビタミンD補充は、妊娠中の女性およびその児の特定の健康状態を改善し、妊娠の有害転帰のリスク（危険）を低減するのに役立つ可能性がある。 {1＞公衆衛生への影響＜1｝ 妊娠中のビタミンD不足は、妊娠中の女性およびその児の健康合併症と関連している。このような合併症を予防する上で、妊娠中のビタミンD補充は必要であると考えられている。 何を調べようとしたのか？ 妊娠中のビタミンD補充が、妊娠中の女性およびその児の特定の健康結果（早産や低出生体重児の減少など）を安全に改善し、妊娠の有害転帰（過度の出血など）のリスク（危険）を減少させるかどうかを評価すること 本レビューで行ったこと 本レビューは2012年に初版が発表され、その後2016年と2019年に更新されたレビューの最新版である。妊娠中のビタミンD補充について、単独またはカルシウムや他のビタミン・ミネラルとの併用で、プラセボまたは介入なしと比較した臨床試験を検索した（2022年12月）。各研究の信頼性を評価するツール を用いて検証した。 研究の結果を比較、要約し、研究方法や規模などの要因に基づいて、情報の信頼性を評価した。 何を見つけたのか？ 本レビューの旧版には30件の研究が含まれていた。今回の更新では、これらの研究のうち20件を「分類待...

Cochrane's strength lies in its collaborative, global community. Cochrane Geographic Groups represent Cochrane in their host countries, advocating for the use of Cochrane evidence in health policy and practice, and supporting Cochrane's members and supporters locally. Here, we spotlight the impactful work of Cochrane Iran, dedicated to increasing the use of best evidence to inform healthcare decision-making across Iran, the Middle East, and neighbouring regions. 

Established in 2017 at the National Insititute for Medical Research Development (NIMAD), Cochrane Iran has swiftly become a pivotal part of Cochrane's global network. By aligning with Cochrane's strategy, Cochrane Iran has significantly expanded its membership, growing from 965 members in 2019 to over 2,100 by mid-2024. 

Cochrane Iran has been a leader in providing hands-on learning through 50 in-person and virtual training sessions and contributed in the nine Continuing Medication Education events, furthering professional development in evidence-based healthcare. They share Cochrane’s recorded online learning events on Aparat, a local video-sharing platform, where the 671 videos have attracted 42,573 views. They co-authored the 4th and 5th editions of the influential book Systematic Review and Meta-Analysis, now a reference in national University courses. In collaboration with Iranian universities, they hosted five journal club sessions, promoting critical evaluation of research findings.

"Our mission at Cochrane Iran is to bridge the gap between research and practice by making high-quality evidence accessible and understandable. We believe that informed decision-making can transform healthcare outcomes across the Middle East."

— Dr. Farid Najafi, Director of Cochrane Iran

Cochrane Iran spearheaded the translation of numerous evidence-based resources, including:

• Over 6,000 abstracts and plain language summaries of Cochrane reviews.
• 72 podcasts explaining Cochrane evidence in under five minutes.
• 27  blogshots for social media that summarize Cochrane reviews.
• Persian Wikipedia pages related to medicine, such as asthma and influenza. 
• Testing Treatments book and audio clips, which champion critical thinking in healthcare.
• The Health Choices Book for children, fostersing critical thinking from a young age.
• Lifeology flashcard courses on preventing infodemics and empowering informed decision-making.
• World Evidence-Based Heathcare Day documents, promoting evidence-based healthcare globally annually.

Their advocacy and dissemination efforts extended to showcasing Cochrane and Cochrane Iran through 50 events and establishing a robust online presence on multiple platforms including Telegram, X, Instagram, and LinkedIn, engaging a large community and promoting evidence-based healthcare practices.

Cochrane Iran actively collaborated with the 10th Iranian National Epidemiology Congress in 2023, featuring a keynote speech by Cochrane CEO Catherine Spencer and leading a thematic panel on adapting WHO guidelines, evidence-based medicine, and Cochrane Iran's achievements. They also this year organised a citizen science challenge on Cochrane Crowd. Participants classified 78,692 records, identifying around 4,000 randomized controlled trials that will aid systematic reviewers worldwide in their research.

Cochrane Iran’s partnership with NIMAD has led to the launch of the Cochrane Evidence Synthesis in the Iranian Primary Health Care System project. This project has included the translation and local adaptation of the Cochrane Evidence Essentials training course, accessible on Iran's Ministry of Health's website, to promote evidence-based decision-making in primary healthcare settings and empower healthcare professionals with essential skills in evidence synthesis.

Their website, Barpaye, provides scientifically evaluated health claims, answering 49 user queries to date. They also sponsor the fact-checking website Factname Salamat, offering evidence-based answers to health-related questions and claims. 

"Through our collaborative efforts and the translation of essential healthcare resources, we are not only empowering healthcare professionals but also engaging the public in critical thinking about their health. This comprehensive approach is key to advancing evidence-based healthcare in Iran and beyond."

— Dr. Bita Mesgarpour, Co-Director of Cochrane Iran

Cochrane Iran remains dedicated to Cochrane’s vision of enhancing evidence-based healthcare quality and fostering collaboration within the research community. Through their continued efforts, they aim to significantly improve health outcomes and support informed decision-making in healthcare practices.

Cochrane Iran invites individuals and organisations to collaborate and support their mission of advancing evidence-based healthcare in the Middle East. Reach out to CochraneIran@gmail.com and explore the numerous opportunities to contribute to their impactful work. 

• Visit the Cochrane Iran website
• Search and view Cochrane evidence in Persian (Farsi)
• Follow Cochrane Iran on social media
  
  • Aparat
  • Instagram
  • LinkedIn
  • Telegram
  • X
• Find a Cochrane Geographical Group in your country

Friday, August 2, 2024

胃管の位置を確認するのに、超音波検査単独または他の方法との併用は有用か？ 要点 - 胃管の適切な位置を確認するために超音波検査がX線検査に代わる有望な方法であるかどうかは不明である。 - 誤った位置に留置された管を特定する超音波検査の精度を見極めるには、さらなる研究が必要である。 胃管とは何か？なぜ使用されるのか？ 食道は、口と胃をつなぐ筋肉でできた管である。うまく飲み込めない場合は、鼻や口から胃管を挿入して、薬や流動食を直接胃に入れることがある。食道は、肺に空気を送る気管に非常に近いため、注意が必要である。胃管の位置がずれて食べ物や薬が気管に入ると、肺に重度の感染症（肺炎と呼ばれる）やその他の合併症を引き起こす可能性がある。それゆえ、胃管を挿入した後にそのチューブが胃内に正しく留置できているかの確認は重要である。正しい位置に留置できたかどうかは、通常X線検査で確認される。 胃管留置の確認において、X線検査から超音波検査に置き換えることがなぜ重要なのか？ 超音波は、音波を使って体内の画像を作成する画像診断技術である。特に資源が限られている場所では、X線検査よりもアクセスしやすく、便利かもしれない。 知りたかったこと 胃管留置の確認における超音波検査の精度を調べ、超音波検査が標準的な方法としてX線検査に取って代わる可能性を評価したいと考えた。 実施したこと 胃管留置の確認における超...

Title: Managing Editor
Specifications: 12 Months Fixed Term Contract (x 3 posts)
Salary: £42,000 per annum
Location: UK, Germany or Denmark – Remote/Flexible
Directorate: Evidence Production & Method
Closing date: 26 July, 2024

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters around the world. Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into five directorates: Evidence Production and Methods, Publishing and Technology, Development, Chief Executive Office and Finance and Corporate Services.

Reporting to the Senior Managing Editor and working with members of the Editorial Production and Methods Directorate, the role holder will need to have good awareness of Cochrane guidance for different types of standard and complex systematic reviews (intervention, qualitative, diagnostic test accuracy, prognosis, rapid and overview), plan how they will need to be handled in their team, and work to ensure that deadlines are met. The role holder will also be required to ensure that pilots aimed at innovating the editorial process can be supported as needed.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values:

Collaboration: Underpins everything we do, locally and globally.

Relevant: The right evidence at the right time in the right format.

Integrity: Independent and transparent.

Quality: Reviewing and improving what we do, maintaining rigour and trust.

You can expect:

• An opportunity to truly impact health globally.
• A flexible work environment
• A comprehensive onboarding experiences.
• An environment where people feel welcome, heard, and included, regardless of their differences.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations, and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply, please click here.
• The deadline to receive your application is 26 July 2024.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples. 
•        Read our Recruitment Privacy Statement

Friday, July 19, 2024 Category: Jobs

天然歯またはインプラント周囲の歯周病に対する標準治療と抗菌的光線力学療法の併用 要点 成人の歯周病患者に対し、抗菌的光線力学療法（aPDT）を標準治療に追加することが、標準治療のみと比較して有意に効果的であるかどうかについては、結論が出なかった。 天然歯やインプラント周囲の歯周病とは何か？ 歯周病の症状には、歯肉からの出血、歯肉の腫れ、口臭などがある。感染によって歯の周囲の軟組織が損傷し、場合によっては歯を失うこともある。また、インプラント（顎骨に固定された人工の歯）を入れている場合は、インプラント周囲の炎症を患うことがある。 歯周病はどのように治療されているのか？ 1日2回のブラッシングと定期的なデンタルフロスの使用、それに加えて、歯科医師による治療が必要な場合がある。標準的な歯周病治療には、感染部位から手用器具や電動器具を使って細菌を除去することが含まれる。また、抗菌薬を服用しなければならない場合もあるが、抗菌薬に対する耐性菌が増えているため、別の治療法が有効な場合もある。 抗菌的光線力学療法（aPDT）とは、光吸収色素（細菌を除去した後、口腔内の患部に塗布される）と光源（通常は低エネルギーのダイオードレーザーが使用される）を組み合わせたものである。 何を調べようとしたのか？ 歯周病患者に対して、標準治療にaPDTを追加することが、標準治療単独よりも効果的であるかどうかを明ら...

Thursday, July 11, 2024

Thursday, July 11, 2024

Cochrane's strength lies in its collaborative, global community. Cochrane Geographic Groups represent Cochrane in their host countries, advocating for the use of Cochrane evidence in health policy and practice, and supporting Cochrane's members and supporters locally. Here, we spotlight the impactful work of Cochrane Hong Kong, dedicated to increasing the use of best evidence to inform healthcare decision-making across China and neighbouring regions.

Cochrane Hong Kong, officially established in 2019, is situated at The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong. As part of the Cochrane China Network, Cochrane Hong Kong is one of eight affiliate groups across China. Today with over 800 members and supporters, they aim to expand the reach and impact of Cochrane evidence on healthcare practice and build capacity for high-quality evidence production.

Since 2022, Cochrane Hong Kong has led Cochrane Nursing, promoting nursing participation in evidence-based healthcare and actively disseminating Cochrane evidence to diverse nursing audiences. This ensures that nurses are aware of relevant Cochrane reviews that can inform their practice. They run the @CochraneNursing X account to share new evidence, supporting members in their engagement with Cochrane and enhancing the dissemination of evidence in nursing both in the broader Asian region and globally.

The group's translation efforts significantly impact healthcare practices and policies in Hong Kong and across Asia, ensuring that medical professionals and the general population have access to high-quality, evidence-based information. In collaboration with the Cochrane China Network and Cochrane Taiwan, they translate plain language summaries of Cochrane reviews into both simplified and traditional Chinese. Currently, there are 2327 plain language summaries in traditional Chinese and  3842 plain language summaries in simplified Chinese for anyone to search and read, making vital health information more accessible.

In 2022, Cochrane Hong Kong hosted the Knowledge Translation Awards, encouraging global university students to engage in knowledge translation and evidence dissemination. The event concluded with a virtual presentation ceremony to honour the awardees for their innovative contributions to advancing knowledge translation and evidence-based practice. "Cochrane Hong Kong's dedication to translating and disseminating evidence is making a significant impact on healthcare practices in China and beyond," says Professor Wai-tong Chien, Co-Director of Cochrane Hong Kong.

Cochrane Hong Kong offers comprehensive training in systematic reviews and evidence production, empowering health professionals and postgraduate students to conduct high-quality reviews. Their workshops during the 1st Cochrane Hong Kong Symposium and the 7th Pan-Pacific Nursing Conference attracted over 300 delegates. Collaborations with other Cochrane groups and external organisations significantly enhance their impact. In January 2023, they co-organised the 2nd Cochrane China Network Symposium, bringing together global healthcare researchers and experts. They also partnered with Southern Medical University for the 2023 Global Health South Forum and The First Pearl River Implementation Science Symposium (PRISIS).

Cochrane Hong Kong collaborates with the Hospital Authority Hong Kong, which governs all public hospitals in the region. They offer workshops and training on systematic reviews and evidence production. Currently, they are conducting a clinical trial to evaluate an evidence-based detection method for ensuring the correct placement of nasogastric tubes across public hospitals. This partnership aims to enhance evidence-based healthcare decisions, improve clinical practices, and establish or revise standards, guidelines, and policies to ensure the highest quality of care for patients.

Looking ahead, Cochrane Hong Kong will continue producing, translating, and disseminating Cochrane evidence. They will collaborate with healthcare institutions and Cochrane organisations to provide more workshops on evidence-based practice. "Cochrane Hong Kong's future projects will continue to build on our strong foundation, advancing evidence-informed decision-making and improving healthcare outcomes across Asia," notes Professor Janita Chau, Co-Director of Cochrane Hong Kong and Co-Chair of Cochrane Nursing. "We are particularly excited about our upcoming training workshops and fellowship programmes, which will help create the next generation of leaders in evidence-based healthcare."

Cochrane Hong Kong invites individuals and organisations in Asia that are eager to impact healthcare to collaborate and offer their support. If you are interested in contributing to their mission, please reach out at cochranehk@cuhk.edu.hk. There are numerous opportunities to engage and contribute to evidence-based healthcare!

• Visit the Cochrane Hong Kong website
• Visit the Cochrane Nursing Field website
• Search and view Cochrane evidence in simplified Chinese
• Search and view Cochrane evidence in traditional Chinese
• Find a Cochrane Geographic Group in your country

Friday, July 19, 2024

Global leaders in evidence-based healthcare - JBI, Cochrane, Campbell Collaboration, AHRU at the University of Oxford, and Institute of Development Studies (IDS) - have joined forces to launch the World Evidence-Based Healthcare (EBHC) Day 2024 campaign: "Health and Beyond: From Evidence to Action."

The World EBHC Day 2024 campaign seeks to galvanise the global evidence community in addressing the interconnected crises facing humanity. These simultaneous and interconnected crises, or ‘polycrisis’, threaten the achievement of the United Nations Sustainable Development Goals and the well-being of people worldwide.

In the face of escalating social, economic, and ecological challenges, the 2024 campaign underscores the need for greater intersectoral action and collaboration to build resilient evidence support systems.

“In a time of ongoing crises, World EBHC Day 2024 presents an important opportunity to bring together the global evidence community to find solutions collaboratively. Cochrane is pleased to be a partner and aims to ensure that momentum from the campaign continues, as there is much to be done to build a healthier world for future generations,” said Catherine Spencer, Cochrane Chief Executive Officer. 

The World EBHC Day 2024 campaign calls on organisations and individuals to share their experiences, innovations, and lessons learned in using evidence-based approaches to drive meaningful change. By facilitating dialogue and knowledge-sharing across sectors, World EBHC Day 2024 serves as a global platform to share and access collective knowledge and wisdom for health and beyond, moving from evidence to action, while highlighting that interdisciplinary collaboration and innovation is pivotal to transformative change.

 Cochrane’s Editor-in-Chief, Dr Karla Soares-Weiser, also shared her enthusiasm for the campaign: “World Evidence-Based Healthcare Day 2024 demonstrates how it is essential to co-create solutions for the complex global challenges of our time. This aligns with the work we have been doing at Cochrane to develop our new Scientific Strategy, which will be published later this year.” 

JBI, Cochrane, The Campbell Collaboration, AHRU at University of Oxford and IDS call on the global evidence community to share their experiences, challenges, innovations, lessons learned, and promising failures in using evidence-based approaches to take action for health and beyond. 

• For more information on the World Evidence-Based Healthcare Day 2024 campaign and how to participate please visit https://worldebhcday.org 
• If you are interested in writing a blog or recording a vlog for World EBHC Day 2024, please get in touch with msalman@cochrane.org

About World EBHC Day: World Evidence-Based Healthcare (EBHC) Day is held on 20 October each year. It is a global initiative that was founded by JBI that raises awareness of the need for better evidence to inform healthcare policy, practice and decision making in order to improve health outcomes globally. It is an opportunity to participate in debate about global trends and challenges, but also to celebrate the impact of individuals and organisations worldwide, recognising the work of dedicated researchers, policymakers and health professionals in improving health outcomes.  For more information, please visit www.worldebhcday.org

Wednesday, July 17, 2024